Erenumab for Migraine

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
MigraineErenumab - Drug
Eligibility
18 - 99
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study how well erenumab works to improve satisfaction with migraine medication.

Eligible Conditions
  • Migraine

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: Week 24

Baseline and Week 24
Mean Change from Baseline in Emotional Function Domain Score as Measured by the MFIQ at Week 24
Mean Change from Baseline in Physical Function Domain Score as Measured by the Migraine Functional Impact Questionnaire (MFIQ) at Week 24
Mean Change from Baseline in Social Function Domain Score as Measured by the MFIQ at Week 24
Mean Change from Baseline in Usual Activities Domain Score as Measured by the MFIQ at Week 24
Mean Change from Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) Overall Satisfaction Scale Score at Week 24
Week 24
Number of Clinician's Reporting Improvement in Treating Clinician's Global Impression at Week 24
Number of Key Family Member's Reporting Improvement in Key Family Member's Impression at Week 24
Number of Participants Achieving Overall Satisfaction at Week 24
Number of Participants Reporting Improvement in Participant Global Impression at Week 24

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Side Effects for

140 mg Erenumab SC
16%Constipation
6%Covid-19
This histogram enumerates side effects from a completed 2021 Phase 4 trial (NCT04294147) in the 140 mg Erenumab SC ARM group. Side effects include: Constipation with 16%, Covid-19 with 6%.

Trial Design

1 Treatment Group

Erenumab
1 of 1

Experimental Treatment

322 Total Participants · 1 Treatment Group

Primary Treatment: Erenumab · No Placebo Group · Phase 4

Erenumab
Drug
Experimental Group · 1 Intervention: Erenumab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Erenumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 24

Who is running the clinical trial?

AmgenLead Sponsor
1,296 Previous Clinical Trials
1,328,496 Total Patients Enrolled
17 Trials studying Migraine
6,410 Patients Enrolled for Migraine
MDStudy DirectorAmgen
838 Previous Clinical Trials
897,597 Total Patients Enrolled
17 Trials studying Migraine
6,410 Patients Enrolled for Migraine

Eligibility Criteria

Age 18 - 99 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have had migraine for at least 12 months.
You have a history of migraine with or without aura for at least 3 months on average across the 3 months prior to screening.
You report to your provider intolerance or insufficient response with your current preventative treatment.